Share-based Payment Arrangement, Expense of AN2 Therapeutics, Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AN2 Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • AN2 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $801,000, a 58% decline year-over-year.
  • AN2 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,626,000, a 25% decline year-over-year.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,338,000, a 0.88% decline from 2023.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8,412,000, a 92% increase from 2022.
  • AN2 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,391,000, a 351% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AN2 Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,626,000 $801,000 -$1,101,000 -58% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $7,727,000 $1,998,000 -$273,000 -12% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $8,000,000 $2,047,000 -$338,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $8,338,000 $1,780,000 -$518,000 -23% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
Q3 2024 $8,856,000 $1,902,000 -$267,000 -12% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $9,123,000 $2,271,000 +$328,000 +17% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $8,795,000 $2,385,000 +$383,000 +19% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $8,412,000 $2,298,000 +$826,000 +56% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
Q3 2023 $7,586,000 $2,169,000 +$941,000 +77% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $6,645,000 $1,943,000 +$701,000 +56% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $5,944,000 $2,002,000 +$1,553,000 +346% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $4,391,000 $1,472,000 +$1,038,000 +239% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $3,353,000 $1,228,000 +$875,000 +248% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $2,478,000 $1,242,000 +$1,063,000 +594% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $1,415,000 $449,000 +$441,000 +5512% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $974,000 $434,000 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $353,000 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $179,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $8,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1

AN2 Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,338,000 -$74,000 -0.88% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
2023 $8,412,000 +$4,021,000 +92% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
2022 $4,391,000 +$3,417,000 +351% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $974,000 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.